Cancer Chemotherapy and Pharmacology

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy
Cancer Chemotherapy and Pharmacology - Tập 11 - Trang S47-S50 - 1983
Yoshizo Nakagami, Tatsuo Minowa, Kazuhiko Tozuka, Yasunori Hiraoka, Hansui Chin
The relapse rate of bladder cancer (transitional cell Ca) is said to be about 45%–80% even after tumor resection. Multidisciplinary treatment was designed and studied to prevent such recurrence. This treatment was designed to have three steps: induction, consolidation, and maintenance therapy. Following surgical tumor removal, OK-432 and Adriamycin (ADM) were administered as consolidation therapy,...... hiện toàn bộ
Acute neurological toxicity of intrathecal cytosine arabinoside
Cancer Chemotherapy and Pharmacology - Tập 16 - Trang 306-307 - 1986
S. Michael Crawford, Gordon J. S. Rustin, Kenneth D. Bagshawe
A patient developed severe neurological toxicity, with peripheral and cerebral components and hyponatraemia following one intrathecal injection of 80 mg cytosine arabinoside. The severity of his symptoms may reflect heavy prior neurotoxic chemotherapy.
Treatment of multiple myeloma with deoxycoformycin
Cancer Chemotherapy and Pharmacology - Tập 14 Số 1 - Trang 49-52 - 1985
AR Belch, Henderson Jf, Brox Lw
A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer
Cancer Chemotherapy and Pharmacology - Tập 82 - Trang 829-838 - 2018
Min Huang, Hong Zhu, Cheng Yi, Juan Yan, Lijia Wei, Xi Yang, Shouchun Chen, Ying Huang
Pancreatic cancer is a malignant tumor of the digestive system with poor prognosis and high mortality, and the treatment of pancreatic cancer still remains a major challenge. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis selectively in cancer cells while causing virtually no damage to normal cells, which is promising for cancer therapy. However, many primary ...... hiện toàn bộ
Characterization and outcomes of patients enrolled to multiple phase I cancer trials
Cancer Chemotherapy and Pharmacology - Tập 85 - Trang 469-472 - 2019
Nathan Kuehne, Lina Chen, Kate McDonald, Lisa Wang, Anna Spreafico, Aaron Hansen, Albiruni Ryan Abdul Razak, Philippe Lucien Bedard, Lillian L. Siu, Daniel Shepshelovich
Some patients who participate in early phase cancer trials enroll to more than one trial. Whether these patients have different characteristics or outcomes than patients who enroll to a single phase I trial is unknown. The study included all patients who participated in the solid tumor drug development program of the Princess Margaret Cancer Centre, a specialized academic cancer center, from July ...... hiện toàn bộ
A phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study
Cancer Chemotherapy and Pharmacology - Tập 34 - Trang 179-180 - 1994
George B. Selby, Christine Upchurch, Jeannette Townsend, Harmon J. Eyre
Sequential vinorelbine–capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial
Cancer Chemotherapy and Pharmacology - Tập 62 - Trang 11-18 - 2007
Marwan Ghosn, Joseph Kattan, Fadi Farhat, Fariha Younes, Fadi Nasr, Walid Moukadem, Jamal Gasmi, Georges Chahine
To evaluate the response rate of the combination of capecitabine (C) and vinorelbine (V) followed by Docetaxel (D) in the 1st line treatment of advanced and metastatic breast cancer patients. Patients with measurable disease and no prior chemotherapy in advanced disease were eligible. Pts received V 25 mg/m2 on day 1 and 8 in combination with C 825 mg/m2 twice a day from day 1 to 14 every 3 weeks ...... hiện toàn bộ
Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
Cancer Chemotherapy and Pharmacology - Tập 67 - Trang 519-525 - 2010
David Goldstein, M. Corona Gainford, Chris Brown, Niall Tebbutt, Stephen P. Ackland, Guy van Hazel, Michael Jefford, Ehtesham Abdi, Sid Selva-Nayagam, Val Gebski, Danielle Miller, Jenny Shannon
Biliary tract cancers (BTC) have a poor prognosis, and there is no consensus on the best chemotherapy regimen. This study determined the response rate for fixed-dose-rate (FDR) gemcitabine combined with cisplatin. This multicentre phase II trial enrolled 50 patients with inoperable locally advanced or metastatic BTC. Treatment consisted of FDR gemcitabine 1,000 mg/m2 (10 mg/m2/min) and cisplatin 2...... hiện toàn bộ
Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo
Cancer Chemotherapy and Pharmacology - Tập 42 - Trang 429-432 - 1998
Simon P. Langdon, Genevieve J. Rabiasz, Alison A. Ritchie, Uwe Reichert, Peter Buchan, William R. Miller, John F. Smyth
The activity of CD437{6-[3-(1-adamantyl)-4 hydroxyphenyl]-2-naphthalene carboxylic acid}, a relatively selective activator of RAR-γ, was evaluated against four human ovarian-carcinoma cell lines : PE01, PE04 (a Pt-resistant in vivo-derived counterpart of PE01), PE01CDDP (a Pt-resistant in vitro-derived model of PE01) and PE014. Growth inhibition was observed after 3 and 6 days of exposure to sub-...... hiện toàn bộ
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
Cancer Chemotherapy and Pharmacology - Tập 66 Số 2 - Trang 269-276 - 2010
Kaori Fujimoto-Ouchi, Fumiko Sekiguchi, Kohsuke Yamamoto, Masatoshi Shirane, Yoshihisa Yamashita, Kazushige Mori
Tổng số: 6,166   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10